ADMA
$1.61
Adma Biologics
$.03
1.90%
ADMA
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.15)
Revenue:  $16.42 Mil
Wednesday
Aug 4
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADMA reports earnings?
Beat
Meet
Miss

Where is ADMA's stock price going from here?
Up
Flat
Down
Stock chart of ADMA
Analysts
Summary of analysts' recommendations for ADMA
Score
Grade
Pivots
Resistance
$1.69
$1.65
$1.63

$1.59

Support
$1.57
$1.54
$1.51
Tweet
Growth
Description
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
Peers
Vertex PharmaceuticalsRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptPfizerUltragenyx PharmaceuticalZoetisMerck & Co.Eli Lilly